Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of MT-2111 in relapsed/refractory diffuse large B-cell lymphoma
jRCT2021220031Phase 2Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Overall response rate. Started Jan 2023; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on jRCT2021220031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220031.